Data that empower: The success and promise of CF patient registries. (Q40041155)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

title

Data that empower: The success and promise of CF patient registries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Aliza K Fink

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Deena R Loeffler

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Bruce C Marshall

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Wayne J Morgan

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

language of work or name

1 reference

14 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

published in

Pediatric Pulmonology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

issue

S48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

page(s)

S44-S51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

30 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Cystic fibrosis in Australia, 2009: results from a data registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Future trends in cystic fibrosis demography in 34 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Gender differences in outcomes of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Median household income and mortality rate in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Cystic fibrosis genetics: from molecular understanding to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Predictive 5-year survivorship model of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Risk factors for mortality before age 18 years in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Survival effect of lung transplantation among patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Cancer Risk in Nontransplanted and Transplanted Cystic Fibrosis Patients: A 10-Year Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

An official American Thoracic Society research statement: comparative effectiveness research in pulmonary, critical care, and sleep medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Confounding by Indication in Clinical Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Children and young adults with CF in the USA have better lung function compared with the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

The yin and yang of indoor airborne exposures to endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Cystic Fibrosis Adult Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Factors influencing outcomes in cystic fibrosis: a center-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

Redesigning care to meet national recommendation of four or more yearly clinic visits in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23790

21 January 2018

Identifiers

DOI

10.1002/PPUL.23790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28910520%20AND%20SRC:MED&resulttype=core&format=json